Sensus Healthcare Fourth Quarter 2022 Financial Results Include Quarterly Revenues of $13.1 Million
BOCA RATON, Fla., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions (Company or Sensus), announces financial results for the three and 12 months ended December 31, 2022.
- Cost of sales for the fourth quarter of 2022 was $4.8 million, compared with $4.2 million for the prior-year quarter.
- Gross profit for the fourth quarter of 2022 was $8.4 million, or 63.7% of revenues, compared with $8.9 million, or 68.0% of revenues, for the fourth quarter of 2021.
- Selling and marketing expense for the fourth quarter of 2022 was $1.6 million, compared with $1.3 million for the fourth quarter of 2021.
- Adjusted EBITDA for the fourth quarter of 2022 was $4.3 million, compared with $5.6 million for the fourth quarter of 2021.